Trending

biosimilars

Javaad Asghari joins J+D from Global Data

Javaad Asghari joins J+D from Global Data

Javaad joins J+D from Global Data

X

Javaad Asghari joins J+D from Global Data

https://pharmaphorum.com/partner-content/javaad-asgahri-joins-jd-from-global-data/

AbbVie wobbles as biosimilars bite Humira

AbbVie wobbles as biosimilars bite Humira

AbbVie’s shares slipped ahead of the weekend when its fourth-quarter revenues missed forecasts, after biosimilar competition – particularly

X

AbbVie wobbles as biosimilars bite Humira

https://pharmaphorum.com/news/abbvie-wobbles-as-biosimilars-bite-humira/

The Pharma Forecasting Workshop – Fundamentals of Forecasting, Zurich

The Pharma Forecasting Workshop – Fundamentals of Forecasting, Zurich

J+D Interactive Pharma Forecasting Workshop

X

The Pharma Forecasting Workshop – Fundamentals of Forecasting, Zurich

https://jdforecasting.com/training/multi-client/

Mycenax’s Actemra biosimilar edges closer to approval

Mycenax’s Actemra biosimilar edges closer to approval

Mycenax’s biosimilar of Roche’s Actemra (tocilizumab), LusiNEX, has been shown to match its originator’s profile in a phase

X

Mycenax’s Actemra biosimilar edges closer to approval

https://pharmaphorum.com/news/mycenaxs-actemra-biosimilar-edges-closer-to-approval/

2018 in review: Humira biosimilars arrive in Europe

2018 in review: Humira biosimilars arrive in Europe

The emergence this year of Humira biosimilars in Europe followed a period of sustained momentum around the cheaper

X

2018 in review: Humira biosimilars arrive in Europe

https://pharmaphorum.com/views-analysis-sales-marketing/2018-review-humira-biosimilars-europe/

Celltrion/Teva’s Herceptin biosimilar approved in US

Celltrion/Teva’s Herceptin biosimilar approved in US

The FDA has approved Celltrion and Teva’s biosimilar of Roche’s breast cancer drug Herceptin, the second potential competitor

X

Celltrion/Teva’s Herceptin biosimilar approved in US

https://pharmaphorum.com/news/celltrion-tevas-herceptin-biosimilar-approved-in-us/

Boehringer Ingelheim axes biosimilars development outside US

Boehringer Ingelheim axes biosimilars development outside US

Boehringer Ingelheim has said it has axed ex-US development of its biosimilars, focusing instead on getting its Humira

X

Boehringer Ingelheim axes biosimilars development outside US

https://pharmaphorum.com/news/boehringer-ingelheim-axes-biosimilars-development-outside-us/

NHS saving £300m with Humira biosimilar deal

NHS saving £300m with Humira biosimilar deal

The NHS is to save £300 million after striking deals with several manufacturers of low cost biosimilars of

X

NHS saving £300m with Humira biosimilar deal

https://pharmaphorum.com/news/nhs-saving-300m-with-humira-biosimilar-deal/

Mundipharma’s Neulasta biosimilar approved in EU

Mundipharma’s Neulasta biosimilar approved in EU

A second cut-price biosimilar of Amgen’s Neulasta (pegfilgrastim) long-acting white blood cell booster is to hit the EU

X

Mundipharma’s Neulasta biosimilar approved in EU

https://pharmaphorum.com/news/mundipharmas-neulasta-biosimilar-approved-in-eu/

1 2 3 4 5 >»

CONTINUE TO SITE >

Close in 10 seconds

Pharmaphorum.com